Anti-CD38 antibody [BLR123H] - BSA free,Abcam,AB314061

REACH authorisation Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances. It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Host

Rabbit

Reactivity

Human

Application

ICC, IP, IHC-P, Flow Cyt, WB

Platform ID

BAB688592519

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-CD38 antibody [BLR123H] - BSA free
Cat. No.AB314061
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationICC, IP, IHC-P, Flow Cyt, WB
ClonalityMonoclonal
Clone NumberBLR123H
Concentration1 mg/mL Batch dependent concentration
ImmunogenRecombinant Fragment Protein within Human CD38 aa 1 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.8 - 8.6 Preservative: 0.09% Sodium azide Constituents: 98% Borate buffered saline
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion (PubMed : 7961800, PubMed : 8253715). Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+) (PubMed : 16690024). Has cADPR hydrolase activity (PubMed : 7961800, PubMed : 8253715). See full target information CD38

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.